Niagen Bioscience

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NAGE and other ETFs, options, and stocks.

About NAGE

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). 

CEO
Robert N. Fried
CEORobert N. Fried
Employees
104
Employees104
Headquarters
Los Angeles, California
HeadquartersLos Angeles, California
Founded
1999
Founded1999
Employees
104
Employees104

NAGE Key Statistics

Market cap
537.65M
Market cap537.65M
Price-Earnings ratio
27.16
Price-Earnings ratio27.16
Dividend yield
Dividend yield
Average volume
770.95K
Average volume770.95K
High today
$6.86
High today$6.86
Low today
$6.59
Low today$6.59
Open price
$6.65
Open price$6.65
Volume
233.64K
Volume233.64K
52 Week high
$14.69
52 Week high$14.69
52 Week low
$5.16
52 Week low$5.16

Stock Snapshot

The current Niagen Bioscience(NAGE) stock price is $6.64, with a market capitalization of 537.65M. The stock trades at a price-to-earnings (P/E) ratio of 27.16.

As of 2025-12-26, Niagen Bioscience(NAGE) stock has fluctuated between $6.59 and $6.86. The current price stands at $6.64, placing the stock +0.7% above today's low and -3.3% off the high.

Niagen Bioscience(NAGE) shares are trading with a volume of 233.64K, against a daily average of 770.95K.

In the last year, Niagen Bioscience(NAGE) shares hit a 52-week high of $14.69 and a 52-week low of $5.16.

In the last year, Niagen Bioscience(NAGE) shares hit a 52-week high of $14.69 and a 52-week low of $5.16.

NAGE News

TipRanks 2d
Niagen Bioscience: Strengthened NR Patent Control and Differentiated Efficacy Support Buy Rating and $14 Target

Niagen Bioscience, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Susan Anderson from Canaccord Genuity maintained a B...

TipRanks 4d
Niagen Bioscience acquires existing nicotinamide riboside patent portfolio

Niagen Bioscience (NAGE) announced that it has acquired a portfolio of existing patents covering nicotinamide riboside and its salt forms from Queen’s Universit...

People also own

Based on the portfolios of people who own NAGE. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.